Publication details

 

IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen

Basic information
Original title:IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen
Authors:Zdeněk Adam, Marta Krejčí, Luděk Pour, Josef Feit, Tomáš Büchler, Roman Hájek
Further information
Citation:ADAM, Zdeněk, Marta KREJČÍ, Luděk POUR, Josef FEIT, Tomáš BÜCHLER a Roman HÁJEK. IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen. Wiener klinische Wochenschrift, Wien: Springer, 2010, roč. 122, 9-10, s. 311-314. ISSN 0043-5325.Export BibTeX
@article{888880,
author = {Adam, Zdeněk and Krejčí, Marta and Pour, Luděk and Feit, Josef and Büchler, Tomáš and Hájek, Roman},
article_location = {Wien},
article_number = {9-10},
keywords = {IgA pemphigus;bortezomib; rituximab; monoclonal gammopathy},
language = {eng},
issn = {0043-5325},
journal = {Wiener klinische Wochenschrift},
title = {IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen},
volume = {122},
year = {2010}
}
Original language:English
Field:Oncology and hematology
Type:Article in Periodical
Keywords:IgA pemphigus;bortezomib; rituximab; monoclonal gammopathy

Monoclonal gammopathy-associated IgA pemphigus is a debilitating skin disorder with inconsistent response to treatment. A 61-year-old woman with IgA pemphigus and monoclonal gammopathy of unknown significance had been treated with bortezomib, cyclophosphamide and dexamethasone regimen, which resulted in complete and durable remission of multiple myeloma and IgA pemphigus. This suggests that bortezomib-based therapy is useful for the treatment of the rare dermatologic disorder associated with IgA gammopathy.

Related projects: